Trump has a small personal financial interest in company that makes brand-name version of hydroxychloroquine: NYT

Trump has a small personal financial interest in company that makes brand-name version of hydroxychloroquine: NYT
President Donald J. Trump, joined by Vice President Mike Pence and members of the White House Coronavirus Task Force, addresses his remarks at a coronavirus (COVID-19) update briefing Wednesday, March 18, 2020, in the James S. Brady Press Briefing Room of the White House. (Official White House Photo by Shealah Craighead)

As Donald Trump uses his daily coronavirus task force briefings as substitute campaign rallies, he continues to hype the antimalarial drug hydroxychloroquine for patients suffering from COVID-19, an unproven treatment that cardiologists warn increases the risk of cardiac arrest.

According to Axios, the president’s push of the antimalarial drug hydroxychloroquine even resulted in an “epic Situation Room showdown” on Saturday as Trump and trade advisor Peter Navarro championed what the president believes could be a “game-changer” in the fight against the coronavirus. During that “showdown, Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases, noted “there was only anecdotal evidence that hydroxychloroquine works against the coronavirus,” resulting in a “confrontation” between Navarro and the nation’s leading doctor.

The battle over hydroxychloroquine spilled out in public on Sunday when Trump, at a press briefing, refused to let Fauci answer a question about the drug. During that same presser, Trump announced he has 29 million doses of hydroxychloroquine in the Strategic National Stockpile.

Brooklyn Hospital Center critical care Dr. Joshua Rosenberg told the New York Times he “understands” why Trump is pushing hydroxychloroquine, insisting the president “has to project hope.”

But there could also be another reason why Trump is leaning heavily on an unproven coronavirus treatment that, as he himself acknowledged, can have a negative impact on “the heart stuff.”

Per the Times: “Mr. Trump himself has a small personal financial interest in Sanofi, the French drugmaker that makes Plaquenil, the brand-name version of hydroxychloroquine.”

Navarro, who warned Trump in late January that more than a half-million Americans could die from coronavirus, was asked about his Situation Room battle with Fauci on CNN Monday. Pressed on what qualifies him to hype hydroxychloroquine as a possible COVID-19 treatment, Navarro cited his credentials as a social scientist.

“I have a Ph.D. And I understand how to read statistical studies, whether it’s in medicine, the law, economics or whatever,” Navarro said.

And while Fauci told Fox News on Friday that “we still need to do the kinds of studies that definitively prove whether any intervention, not just this one, any intervention is truly safe and effective,” the president is making clear he’s ready to go all-in on hydroxychloroquine.

“We don’t have time,” Trump said at his Sunday press conference. “We don’t have two hours because there are people dying right now.”

Time is money, after all.

Enjoy this piece?

… then let us make a small request. AlterNet’s journalists work tirelessly to counter the traditional corporate media narrative. We’re here seven days a week, 365 days a year. And we’re proud to say that we’ve been bringing you the real, unfiltered news for 20 years—longer than any other progressive news site on the Internet.

It’s through the generosity of our supporters that we’re able to share with you all the underreported news you need to know. Independent journalism is increasingly imperiled; ads alone can’t pay our bills. AlterNet counts on readers like you to support our coverage. Did you enjoy content from David Cay Johnston, Common Dreams, Raw Story and Robert Reich? Opinion from Salon and Jim Hightower? Analysis by The Conversation? Then join the hundreds of readers who have supported AlterNet this year.

Every reader contribution, whatever the amount, makes a tremendous difference. Help ensure AlterNet remains independent long into the future. Support progressive journalism with a one-time contribution to AlterNet, or click here to become a subscriber. Thank you. Click here to donate by check.

DonateDonate by credit card


Thanks for your support!

Did you enjoy AlterNet this year? Join us! We're offering AlterNet ad-free for 15% off - just $2 per week. From now until March 15th.